Viva Biotech Holdings posts mixed H1 2025 results despite revenue dip

Viva Biotech Holdings announced its interim results for the six months ended June 30, 2025, with revenue decreasing by approximately 15.3% to RMB831.9 million, down from RMB981.8 million in the corresponding period last year. This decline was primarily attributed to a decrease in CDMO revenue. Despite the revenue fall, the company's gross profit margin improved significantly to 40.8%, an increase of 6.3 percentage points from 34.5% in H1 2024, driven by business structure optimization and enhanced operational efficiency in the CRO business.

Net profit for the period increased by 3.1% year-over-year to RMB148.6 million from RMB144.2 million in H1 2024. Adjusted non-IFRS net profit also saw a rise of approximately 9.1% to RMB183.5 million, compared to RMB168.2 million in the prior year. Basic earnings per share attributable to ordinary equity holders of the parent stood at RMB0.06, up from RMB0.05 in 2024.

The company's CRO business revenue increased by approximately 9.6% to RMB422.8 million, with adjusted gross profit rising by 16.4% to RMB194.6 million. This growth was boosted by recovery in global biopharmaceutical investment and a surge in domestic innovative drug BD transactions. Conversely, Langhua Pharmaceutical's revenue decreased by approximately 31.4% to RMB409.0 million due to workshop upgrades, supply chain disruptions, and the timing of new CDMO projects.